Bausch Noncontrolling Interest In Consolidated Entity from 2010 to 2024
| BHC Stock | USD 8.18 0.01 0.12% |
Noncontrolling Interest In Consolidated Entity | First Reported 2010-06-30 | Previous Quarter 945 M | Current Value 934 M | Quarterly Volatility 262.6 M |
Check Bausch Health financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bausch Health's main balance sheet or income statement drivers, such as Depreciation And Amortization of 884.5 M, Interest Expense of 1.4 B or Selling General Administrative of 2.4 B, as well as many indicators such as Price To Sales Ratio of 0.32, Dividend Yield of 0.0522 or Days Sales Outstanding of 95.54. Bausch financial statements analysis is a perfect complement when working with Bausch Health Valuation or Volatility modules.
Bausch | Noncontrolling Interest In Consolidated Entity |
Latest Bausch Health's Noncontrolling Interest In Consolidated Entity Growth Pattern
Below is the plot of the Noncontrolling Interest In Consolidated Entity of Bausch Health Companies over the last few years. It is Bausch Health's Noncontrolling Interest In Consolidated Entity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bausch Health's overall financial position and show how it may be relating to other accounts over time.
| Noncontrolling Interest In Consolidated Entity | 10 Years Trend |
|
Noncontrolling Interest In Consolidated Entity |
| Timeline |
Bausch Noncontrolling Interest In Consolidated Entity Regression Statistics
| Arithmetic Mean | 270,002,600 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 153.90 | |
| Mean Deviation | 318,177,627 | |
| Median | 95,000,000 | |
| Standard Deviation | 415,538,708 | |
| Sample Variance | 172672.4T | |
| Range | 1.1B | |
| R-Value | 0.73 | |
| Mean Square Error | 87480.6T | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | 67,616,729 | |
| Total Sum of Squares | 2417413.9T |
Bausch Noncontrolling Interest In Consolidated Entity History
About Bausch Health Financial Statements
Bausch Health stakeholders use historical fundamental indicators, such as Bausch Health's Noncontrolling Interest In Consolidated Entity, to determine how well the company is positioned to perform in the future. Although Bausch Health investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bausch Health's assets and liabilities are reflected in the revenues and expenses on Bausch Health's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bausch Health Companies. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Noncontrolling Interest In Consolidated Entity | 1.1 B | 1.1 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bausch Health Companies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bausch Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bausch Health Companies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bausch Health Companies Stock:Check out the analysis of Bausch Health Correlation against competitors. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bausch Health. If investors know Bausch will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bausch Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.61) | Earnings Share (0.48) | Revenue Per Share 25.794 | Quarterly Revenue Growth 0.122 | Return On Assets 0.0415 |
The market value of Bausch Health Companies is measured differently than its book value, which is the value of Bausch that is recorded on the company's balance sheet. Investors also form their own opinion of Bausch Health's value that differs from its market value or its book value, called intrinsic value, which is Bausch Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bausch Health's market value can be influenced by many factors that don't directly affect Bausch Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bausch Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bausch Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bausch Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.